HomeCompareRXDX vs MO

RXDX vs MO: Dividend Comparison 2026

RXDX yields 1.00% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $59.0K in total portfolio value· pulled ahead in Year 4
10 years
RXDX
RXDX
● Live price
1.00%
Share price
$199.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$106.75
Full RXDX calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — RXDX vs MO

📍 MO pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRXDXMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RXDX + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RXDX pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RXDX
Annual income on $10K today (after 15% tax)
$85.03/yr
After 10yr DRIP, annual income (after tax)
$90.74/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $25,544.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RXDX + MO for your $10,000?

RXDX: 50%MO: 50%
100% MO50/50100% RXDX
Portfolio after 10yr
$50.6K
Annual income
$15,132.96/yr
Blended yield
29.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

RXDX
Analyst Ratings
4
Buy
7
Hold
Consensus: Hold
Price Target
$138.57
-30.7% upside vs current
Range: $67.00 — $200.00
Altman Z
94.1
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RXDX buys
0
MO buys
0
No recent congressional trades found for RXDX or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRXDXMO
Forward yield1.00%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$21.1K$80.1K
Annual income after 10y$106.75$30,159.17
Total dividends collected$1.0K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$138.57$61.25

Year-by-year: RXDX vs MO ($10,000, DRIP)

YearRXDX PortfolioRXDX Income/yrMO PortfolioMO Income/yrGap
1$10,800$100.04$10,570$780.30+$230.00RXDX
2$11,657$100.98$11,381$1,032.90+$276.00RXDX
3$12,575$101.86$12,535$1,392.73+$40.00RXDX
4← crossover$13,558$102.69$14,193$1,920.91$635.00MO
5$14,610$103.47$16,618$2,723.68$2.0KMO
6$15,737$104.21$20,263$3,993.80$4.5KMO
7$16,944$104.91$25,936$6,098.36$9.0KMO
8$18,235$105.56$35,166$9,775.01$16.9KMO
9$19,618$106.17$51,026$16,597.78$31.4KMO
10$21,098$106.75$80,113$30,159.17$59.0KMO

RXDX vs MO: Complete Analysis 2026

RXDXStock

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Full RXDX Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this RXDX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RXDX vs SCHDRXDX vs JEPIRXDX vs ORXDX vs KORXDX vs MAINRXDX vs PMRXDX vs BTIRXDX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.